Test Bank for Pharmacology for the Primary Care
Provider | 6th Edition | All 54 Chapter Covered
|2026 Update | Constance G. Visovsky, Cheryl H.
Zambroski, Sean L. Sharp
,Unit 1 Principles of Pharmacology for Advanced Practice
Chapter 1 Pharmacokinetics and Pharmacodynamics
1. A 68-year-old man with chronic kidney disease stage 4 is prescribed a renally cleared
antibiotic. Which pharmacokinetic change is most likely to require dose adjustment?
A. Increased hepatic metabolism
B. Reduced glomerular filtration rate
C. Increased plasma protein binding
D. Increased first-pass metabolism
ANS: B
Rationale: Reduced glomerular filtration rate decreases renal clearance, leading to drug
accumulation and increased risk of toxicity. Many antibiotics are eliminated unchanged
by the kidneys, so dosing must be adjusted based on creatinine clearance or estimated
GFR. Hepatic metabolism and first-pass effects are unrelated to renal elimination.
Protein binding changes can alter free drug fraction but are less impactful than impaired
excretion in advanced kidney disease.
2. A patient taking warfarin develops hypoalbuminemia due to liver disease. What is the
expected pharmacodynamic consequence?
A. Decreased free drug concentration
B. Increased free drug concentration
C. Decreased drug efficacy
D. Increased drug elimination
ANS: B
Rationale: Warfarin is highly protein-bound. Hypoalbuminemia reduces available
binding sites, increasing the free fraction of the drug. This enhances anticoagulant effect
and bleeding risk. Free drug is pharmacologically active. Elimination may increase
slightly due to higher free drug, but the dominant clinical effect is increased activity and
toxicity.
3. A medication has a high first-pass effect. Which route of administration would most
increase its bioavailability?
A. Oral
B. Sublingual
C. Rectal
D. Enteral feeding tube
ANS: B
Rationale: Sublingual administration bypasses hepatic first-pass metabolism by entering
systemic circulation directly via venous drainage. Oral and enteral routes undergo
, significant first-pass metabolism. Rectal administration partially bypasses the liver but is
variable and less reliable than sublingual for avoiding first-pass metabolism.
4. A drug has a narrow therapeutic index. What is the most appropriate clinical approach?
A. Prescribe without monitoring
B. Use maximum dosing for efficacy
C. Monitor serum drug levels closely
D. Avoid combination therapy
ANS: C
Rationale: Drugs with a narrow therapeutic index have a small margin between
therapeutic and toxic doses. Monitoring serum levels ensures concentrations remain
within the safe and effective range. Examples include digoxin and lithium. Maximum
dosing increases toxicity risk. Combination therapy is not inherently contraindicated but
requires caution.
5. A patient receives repeated dosing of a drug and reaches steady state. When is steady
state typically achieved?
A. After one half-life
B. After two half-lives
C. After four to five half-lives
D. After ten half-lives
ANS: C
Rationale: Steady state occurs when the rate of drug administration equals the rate of
elimination. This typically takes about four to five half-lives regardless of dose. At this
point, plasma drug concentration plateaus. This principle is essential for timing
therapeutic drug monitoring.
6. A drug demonstrates zero-order kinetics at high doses. What does this imply?
A. Drug elimination rate is proportional to concentration
B. A constant amount of drug is eliminated per unit time
C. Drug is rapidly cleared
D. Drug does not accumulate
ANS: B
Rationale: In zero-order kinetics, elimination pathways are saturated, so a constant
amount of drug is removed per unit time regardless of concentration. This increases risk
of accumulation and toxicity. In contrast, first-order kinetics involves elimination
proportional to concentration.
7. A patient with liver cirrhosis is prescribed a medication extensively metabolized by the
liver. What is the primary concern?
A. Increased renal clearance
, B. Reduced drug bioavailability
C. Increased drug accumulation
D. Increased protein synthesis
ANS: C
Rationale: Liver cirrhosis impairs hepatic metabolism, leading to reduced drug clearance
and accumulation. This increases the risk of adverse effects and toxicity. Bioavailability
may actually increase due to reduced first-pass metabolism. Protein synthesis is
decreased in cirrhosis.
8. A drug has a large volume of distribution. What does this indicate?
A. Drug remains in plasma
B. Drug is confined to extracellular fluid
C. Drug extensively distributes into tissues
D. Drug is rapidly excreted
ANS: C
Rationale: A large volume of distribution indicates that the drug leaves the bloodstream
and accumulates in tissues such as fat or muscle. Lipophilic drugs typically have large
volumes of distribution. Plasma concentrations may appear low despite significant total
body drug content.
9. A patient is given an intravenous loading dose of a medication. What is the purpose?
A. Reduce toxicity
B. Achieve steady state rapidly
C. Prolong drug half-life
D. Increase metabolism
ANS: B
Rationale: A loading dose is used to quickly achieve therapeutic plasma concentrations,
especially for drugs with long half-lives. Without a loading dose, it may take several half-
lives to reach steady state. It does not alter metabolism or half-life.
10. A drug is highly lipophilic. What pharmacokinetic property is expected?
A. Poor tissue penetration
B. Rapid renal excretion
C. Extensive tissue distribution
D. Low protein binding
ANS: C
Rationale: Lipophilic drugs cross cell membranes easily and accumulate in tissues,
leading to a large volume of distribution. They are often metabolized in the liver before
excretion. Hydrophilic drugs are more likely to remain in plasma and be renally excreted.
Provider | 6th Edition | All 54 Chapter Covered
|2026 Update | Constance G. Visovsky, Cheryl H.
Zambroski, Sean L. Sharp
,Unit 1 Principles of Pharmacology for Advanced Practice
Chapter 1 Pharmacokinetics and Pharmacodynamics
1. A 68-year-old man with chronic kidney disease stage 4 is prescribed a renally cleared
antibiotic. Which pharmacokinetic change is most likely to require dose adjustment?
A. Increased hepatic metabolism
B. Reduced glomerular filtration rate
C. Increased plasma protein binding
D. Increased first-pass metabolism
ANS: B
Rationale: Reduced glomerular filtration rate decreases renal clearance, leading to drug
accumulation and increased risk of toxicity. Many antibiotics are eliminated unchanged
by the kidneys, so dosing must be adjusted based on creatinine clearance or estimated
GFR. Hepatic metabolism and first-pass effects are unrelated to renal elimination.
Protein binding changes can alter free drug fraction but are less impactful than impaired
excretion in advanced kidney disease.
2. A patient taking warfarin develops hypoalbuminemia due to liver disease. What is the
expected pharmacodynamic consequence?
A. Decreased free drug concentration
B. Increased free drug concentration
C. Decreased drug efficacy
D. Increased drug elimination
ANS: B
Rationale: Warfarin is highly protein-bound. Hypoalbuminemia reduces available
binding sites, increasing the free fraction of the drug. This enhances anticoagulant effect
and bleeding risk. Free drug is pharmacologically active. Elimination may increase
slightly due to higher free drug, but the dominant clinical effect is increased activity and
toxicity.
3. A medication has a high first-pass effect. Which route of administration would most
increase its bioavailability?
A. Oral
B. Sublingual
C. Rectal
D. Enteral feeding tube
ANS: B
Rationale: Sublingual administration bypasses hepatic first-pass metabolism by entering
systemic circulation directly via venous drainage. Oral and enteral routes undergo
, significant first-pass metabolism. Rectal administration partially bypasses the liver but is
variable and less reliable than sublingual for avoiding first-pass metabolism.
4. A drug has a narrow therapeutic index. What is the most appropriate clinical approach?
A. Prescribe without monitoring
B. Use maximum dosing for efficacy
C. Monitor serum drug levels closely
D. Avoid combination therapy
ANS: C
Rationale: Drugs with a narrow therapeutic index have a small margin between
therapeutic and toxic doses. Monitoring serum levels ensures concentrations remain
within the safe and effective range. Examples include digoxin and lithium. Maximum
dosing increases toxicity risk. Combination therapy is not inherently contraindicated but
requires caution.
5. A patient receives repeated dosing of a drug and reaches steady state. When is steady
state typically achieved?
A. After one half-life
B. After two half-lives
C. After four to five half-lives
D. After ten half-lives
ANS: C
Rationale: Steady state occurs when the rate of drug administration equals the rate of
elimination. This typically takes about four to five half-lives regardless of dose. At this
point, plasma drug concentration plateaus. This principle is essential for timing
therapeutic drug monitoring.
6. A drug demonstrates zero-order kinetics at high doses. What does this imply?
A. Drug elimination rate is proportional to concentration
B. A constant amount of drug is eliminated per unit time
C. Drug is rapidly cleared
D. Drug does not accumulate
ANS: B
Rationale: In zero-order kinetics, elimination pathways are saturated, so a constant
amount of drug is removed per unit time regardless of concentration. This increases risk
of accumulation and toxicity. In contrast, first-order kinetics involves elimination
proportional to concentration.
7. A patient with liver cirrhosis is prescribed a medication extensively metabolized by the
liver. What is the primary concern?
A. Increased renal clearance
, B. Reduced drug bioavailability
C. Increased drug accumulation
D. Increased protein synthesis
ANS: C
Rationale: Liver cirrhosis impairs hepatic metabolism, leading to reduced drug clearance
and accumulation. This increases the risk of adverse effects and toxicity. Bioavailability
may actually increase due to reduced first-pass metabolism. Protein synthesis is
decreased in cirrhosis.
8. A drug has a large volume of distribution. What does this indicate?
A. Drug remains in plasma
B. Drug is confined to extracellular fluid
C. Drug extensively distributes into tissues
D. Drug is rapidly excreted
ANS: C
Rationale: A large volume of distribution indicates that the drug leaves the bloodstream
and accumulates in tissues such as fat or muscle. Lipophilic drugs typically have large
volumes of distribution. Plasma concentrations may appear low despite significant total
body drug content.
9. A patient is given an intravenous loading dose of a medication. What is the purpose?
A. Reduce toxicity
B. Achieve steady state rapidly
C. Prolong drug half-life
D. Increase metabolism
ANS: B
Rationale: A loading dose is used to quickly achieve therapeutic plasma concentrations,
especially for drugs with long half-lives. Without a loading dose, it may take several half-
lives to reach steady state. It does not alter metabolism or half-life.
10. A drug is highly lipophilic. What pharmacokinetic property is expected?
A. Poor tissue penetration
B. Rapid renal excretion
C. Extensive tissue distribution
D. Low protein binding
ANS: C
Rationale: Lipophilic drugs cross cell membranes easily and accumulate in tissues,
leading to a large volume of distribution. They are often metabolized in the liver before
excretion. Hydrophilic drugs are more likely to remain in plasma and be renally excreted.
